Loading clinical trials...
Loading clinical trials...
A Three-Arm, Observational, Pilot Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure
Conditions
Interventions
68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
Locations
1
United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Start Date
November 1, 2025
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
April 27, 2026
NCT07037459
NCT07057466
NCT07093528
NCT07219511
NCT07272902
NCT05839730
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions